Advanced Cancer, Solid Tumor
Conditions
Keywords
Immune checkpoint inhibitor, POLE/POLD mutation, non-MSI-H
Brief summary
The purpose of this study is to evaluate the response of toripalimab (JS001), a PD1 antibody, in participants with POLE or POLD-mutated and non microsatellite instability (non-MSI-H) advanced solid cancers.
Detailed description
Immune checkpoint inhibitor (ICI) therapy including antibodies targeting PD-1/PD-L1 or CTLA-4 has greatly advanced the cancer treatments. Recent studies have identified several predictive markers for ICI which includes microsatellite instability (MSI), PD-L1 expression and tumor mutation burden (TMB). DNA polymerase epsilon (POLE) and delta (POLD) are in charge of DNA replication as well as proofreading during DNA replication. Their germline or somatic mutations can lead to DNA repair deficiencies and carcinogenesis. The investigators has found that the POLE or POLD mutation causes an increased TMB in cancer patients and may lead to a better survival to ICI. Therefore, the purpose of this study is to evaluate the efficacy of toripalimab , a PD1 antibody, in participants with POLE or POLD-mutated and non microsatellite instability high (non-MSI-H) advanced solid cancers. This is a Phase II, open label, single arm study. Participants enrolled in this study received toripalimab 240mg, every 3 weeks until disease progress or intolerable toxicity. Primary endpoints is ORR and secondary endpoints are OS, PFS and safety.
Interventions
DRUGToripalimab
Toripalimab, 240mg, every 3 weeks until disease progress or intolerable toxicity
Sponsors
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Participants must provide written informed consent to participate * Adult aged between 18 and 75 years old * Participants with Histologically- or cytologically- proven advanced solid tumors and not responding to standard therapy * MSS (microsatellite sability) or MSI-L (microsatellite instability-low) or pMMR status * Germline mutations or somatic mutations in POLE or POLD (synonymous mutation is excluded) * Patients refuse any conventional chemotherapy or targeted therapy * Patients are willing to take biopsy of tumor tissue and take blood samples before treatment (blood samples are also taken at each time of therapeutic evaluation) * Participants must have at least one measurable site of disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Lesions previously treated with radiotherapy should not be regarded as target lesions unless there is a definite progression of the lesion after radiotherapy. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Estimated life expectancy is greater than 3 months * Participants can provide more than 10 paraffin sections of tumor tissue * No history of radiotherapy or received non-targeted radiotherapy outside the target lesions for this study more than 4 weeks ago before the first dose of study treatment * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x (5 x in participants with liver metastasis) upper limit of normal (ULN) * Albumin ≥ 3 g/dL * Alkaline phosphatase ≤ 2.5 x ULN. * Serum bilirubin \<1.5 mg/dL * Creatinine ≤ ULN. * Absolute neutrophil count ≥ 1.5X10E9/L * Platelets ≥ 100 x 10E9/L * Hemoglobin ≥ 90 g/L * For females of childbearing potential (defined as \<2 years after last menstruation or not surgically sterile), a negative serum pregnancy test must be performed within 21 days of the first dose of study treatment. * For females: agreement to contraception during the study treatment period and for at least 28 days after the last dose of study treatment
Exclusion criteria
* Patients with confirmed or suspected brain metastases * Patients with cancerous meningitis * Patients without germline mutations or somatic mutations in POLE and POLD * MSI-H (microsatellite instability-high) or dMMR * Prior treatment with PD-1 inhibitors, PD-L1 inhibitors or CTLA-4 inhibitors (or other inhibitors in T cell co-stimulatory signals or checkpoint pathways) * Known history or evidence of cytotoxic drug therapy, biologic drug therapy (such as monoclonal antibodies), immunotherapy (such as interleukin 2 or interferon), or other investigational drugs therapy in the 4 weeks before the first dose of study treatment * Known history or evidence of significant immunodeficiency (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, hyperthyroidism and hypothyroidism; Patients with vitiligo or asthma completely relieved can be included. Asthma that requires medical intervention cannot be included) * Patients with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisolone equivalent) or other immunosuppressive medications * Patients with active tuberculosis. Known history of antituberculosis drugs treatment in 1 year before the first dose of study treatment * Administration of an anti-infection vaccine (e.g. influenza vaccine, chickenpox vaccine) in the 4 weeks before the first dose of study treatment * Symptomatic heart failure, coronary heart disease (CHD), myocardial infarction in the 6 months before the first dose of study treatment * Known allergy to JS001 or its excipients * Pregnant or breastfeeding females * Other prior malignancy active within the previous 5 years except for non-melanoma skin cancer * Persons without legal capacity * Positive test for HIV or AIDS * Positive test for HbsAg and HBV-DNA copy numbers (≥ 1000cps/ml) * Positive test for HCV * Any medical disorder or condition that, in the opinion of the investigator, may affect the compliance or the signing of informed consent, etc.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rates (ORR) | up to 2 years | the ratio of patients whose efficiency evaluation is CR or PR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | up to 2 years | defined as the period from the first dose of study treatment to loss of follow-up or death |
| Progression free survival (PFS) | up to 2 years | defined as the time from the first dose of study treatment to disease progression |
| Adverse Events (AEs) | up to 2 years | All treatment-related adverse events (AEs) were categorized according to the National Cancer Institute's Common Terminology Criteria for Adverse Events. |
Countries
China
Contacts
CONTACTFeng Wang, MD, PhD
CONTACTYING JIN, MD
PRINCIPAL_INVESTIGATORRui-hua Xu, MD, PhD
Sun Yat-Sen University Cancer Center
PRINCIPAL_INVESTIGATORFENG WANG, MD,PhD
Sun Yat-Sen University Cancer Center
PRINCIPAL_INVESTIGATORYing Jin
Sun Yat-Sen University Cancer Center
Outcome results
None listed